This page shows the latest Janssen news and features for those working in and with pharma, biotech and healthcare.
Janssen Pharmaceuticals, a Johnson &Johnson company, has announced positive real-world data for its IL-23 inhibitor Tremfya (guselkumab) in adults with treatment-resistant active psoriatic arthritis (PsA). ... in pain, physical function and fatigue
Janssen, a Johnson &Johnson company, has announced positive results from a mid-stage study of its investigational FcRn inhibitor in rheumatoid arthritis (RA). ... Terence Rooney, vice president and rheumatology disease area leader at Janssen, said:
Wezlana is now approved as a biosimilar to and interchangeable with Janssen Pharmaceuticals’ Stelara (ustekinumab). ... Most recently, Janssen’s Stelara received FDA approval for the treatment of paediatric patients aged six years and older with
GSK and Arrowhead Pharmaceuticals have announced that they have reached an agreement with Janssen Pharmaceuticals to receive exclusive rights to its hepatitis B therapy, JNJ-3989. ... The Johnson &Johnson company’s investigational hepatitis B virus (HBV
The company also signed a deal with Janssen Pharmaceuticals, now Johnson &Johnson Innovative Medicine, to develop and commercialise an experimental vaccine candidate developed by the Johnson &Johnson unit for extraintestinal pathogenic
The positive readout comes just a few months after Nanobiotix gave Janssen Pharmaceuticals – now Johnson &Johnson Innovative Medicine – a worldwide licence for the development and commercialisation of NBTXR3, except in territories
More from news
Approximately 177 fully matching, plus 427 partially matching documents found.
More recently, Janssen saw streamlining opportunities for its content review process with the AI-powered Smart Reviewer system, which picks up language or factual errors and flags information that needs to
Today, leading biologics manufacturers such as Pfizer, BMS, Janssen, Amgen, Sanofi, Takeda, including leading emerging names like MeiraGTx, Horizon, Alexion, BioMarin, have their tech ops and manufacturing sites (bulk drug,
In August 2022, four partners from the PAN-TB collaboration – Janssen Pharmaceutica NV, Otsuka, TB Alliance and Gates MRI – executed a joint development agreement (JDA) supporting the progression of two investigational ... 1. Bedaquiline – a
Jennifer Lee is Therapy Area Market Access Leader for Janssen EMEA.
Personalisation was also cited as one of three key trends shaping the future of our industry, along with commercial excellence and flexibility, by Janssen’s Maria Raad, Janssen EMEA’s vice
More from intelligence
Approximately 5 fully matching, plus 62 partially matching documents found.
Prior to Genmab, Ahmadi worked as head of experimental medicine and early development oncology at Janssen.
During her time at J&J, Torres held several executive leadership roles including president of McNeil Consumer Healthcare and president of Janssen Pharmaceuticals, CNS.
He has also served in various executive leadership roles at Novartis Pharma and Novartis Oncology, and he began his career at Johnson &Johnson and Janssen.
He has previously held roles for ProQR Therapeutics, Janssen BioTherapeutics, and MorphoSys.
Prior to his time at Mundipharma, he served Napp Pharmaceuticals and Janssen in various capacities.
More from appointments
Approximately 3 fully matching, plus 27 partially matching documents found.
Our first confirmed speaker is Daniel de Schryver, Patient Engagement &Advocacy Lead, Europe, Middle-East and Africa, Janssen.
Working with global pharma clients such as Takeda, GSK, Janssen and Abbvie, the consultancy is on a trajectory for growth and has doubled in size due to its commitment to technology,
Recently, Darzalex (daratumumab), a monoclonal antibody developed by Genmab and Janssen, that has been available for the management of patients with multiple myeloma across Europe for 5 years, was granted accelerated
READ MORE ABOUT OUR WINNING PROJECT WITH WITH JANSSEN BELOW:. The Immunology Training Summit (ITS) 2020 with the Janssen EMEA Immunology team took a week-long face-to-face meeting for ... Strikingly this format is now considered best practice in
Clinigen. Crohns and Colitis Department for International Development. Eisai. Gilead. Janssen.
More from PMHub
Approximately 5 fully matching, plus 28 partially matching documents found.
No results were found
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....